Skip to main content
SpringerLink
Log in

Topical emulgel formulation containing inclusion complex of calcipotriol with cyclodextrin

  • Original Article
  • Published:
Journal of Inclusion Phenomena and Macrocyclic Chemistry Aims and scope Submit manuscript

Abstract

Psoriasis is a relatively common, chronic, inflammatory disease that affects the skin, scalp, and joints. Calcipotriol is one of the most commonly used topical agents for the treatment of psoriasis. However, it is a water-insoluble active substance and frequently leads to skin irritation in patients. Cyclodextrins (CDs) are cyclic oligosaccharides consisting of (α-1,4-)-linked d-glucopyranose units. CD molecules have a hydrophilic outer surface and a lipophilic central cavity, and they are able to form inclusion complexes in aqueous solutions with many drugs. They can increase bioavailability, aqueous solubility, and stability and also reduce the side effects of the drugs. The aim of this study was to develop a new topical drug delivery system of calcipotriol in order to improve the solubility and dissolution characteristics of the drug and reduce the undesirable side effects. For this purpose, an inclusion complex of calcipotriol with Captisol® was prepared, and complex formation was confirmed. The inclusion complex and pure drug were formulated separately in an emulgel base. Dissolution profiles of calcipotriol from emulgel formulations were compared with a commercial product of the drug. The drug release was significantly increased with the emulgel formulations compared to the commercial cream product.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Lebwohl, M.: A clinician’s paradigm in the treatment of psoriasis. J. Am. Acad. Dermatol. 53, S59–S69 (2005)

    Article  Google Scholar 

  2. Nelson, A.A., Pearce, D.J., Fleischer, A.B., Balkrishnan, R., Feldman, S.R.: New treatments for psoriasis: which biologic is best? J. Dermatol. Treat. 17, 96–107 (2006)

    Article  Google Scholar 

  3. Laws, P.M., Young, H.S.: Topical treatment of psoriasis. Expert Opin. Pharmacother. 11(12), 1999–2009 (2010)

    Article  CAS  Google Scholar 

  4. Basavaraj, K.H., Navya, M.A., Rashmi, R.: Stress and quality of life in psoriasis: an update. Int. J. Dermatol. 50, 783–792 (2011)

    Article  Google Scholar 

  5. Mendonça, C.O., Burden, A.D.: Current concepts in psoriasis and its treatment. Pharmacol. Ther. 99, 133–147 (2003)

    Article  Google Scholar 

  6. Tiberio, R., Bozzo, C., Pertusi, G., Graziola, F., Gattoni, M., Griffanti, P., Boggio, P., Colombo, E., Leigheb, G.: Calcipotriol induces apoptosis in psoriatic keratinocytes. Clin. Exp. Dermatol. 34, e972–e974 (2009)

    Article  CAS  Google Scholar 

  7. Reich, K., Bewley, A.: What is new in topical therapy for psoriasis? J. Eur. Acad. Dermatol. Venereol. 25(Suppl 4), 15–20 (2011)

    Article  CAS  Google Scholar 

  8. Knudsen, N.Ø., Jorgensen, L., Hansen, J., Vermehren, C., Frokjaer, S., Foged, C.: Targeting of liposome-associated calcipotriol to the skin: effect of liposomal membrane fluidity and skin barrier integrity. Int. J. Pharm. 416(2), 478–485 (2011)

    Article  CAS  Google Scholar 

  9. Knudsen, N.Ø., Rønholt, S., Salte, R.D., Jorgensen, L., Thormann, T., Basse, L.H., Hansen, J., Frokjaer, S., Foged, C.: Calcipotriol delivery into the skin with PEGylated liposomes. Eur. J. Pharm. Biopharm. 81, 532–539 (2012)

    Article  CAS  Google Scholar 

  10. Knudsen, N.Ø., Schiffelers, R.M., Jorgensen, L., Hansen, J., Frokjaer, S., Foged, C.: Design of cyclic RKKH peptide conjugated PEG liposomes targeting the integrin α2β1 receptor. Int. J. Pharm. 428, 171–177 (2012)

    Article  CAS  Google Scholar 

  11. Lin, Y.-K., Huang, Z.-R., Zhuo, R.-Z., Fang, J.-Y.: Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomed. 5, 117–128 (2010)

    CAS  Google Scholar 

  12. Loftsson, T., Jarho, P., Másson, M., Järvinen, T.: Cyclodextrins in drug delivery. Expert Opin. Drug Deliv. 2(2), 335–351 (2005)

    Article  CAS  Google Scholar 

  13. Laza-Knoerr, A.L., Gref, R., Couvreur, P.: Cyclodextrins for drug delivery. J. Drug Target. 18(9), 645–656 (2010)

    Article  CAS  Google Scholar 

  14. Loftsson, T., Brewster, M.E.: Pharmaceutical applications of cyclodextrins: basic science and product development. J. Pharm. Pharmacol. 62, 1607–1621 (2010)

    Article  CAS  Google Scholar 

  15. Loftsson, T., Petersen, D.S.: Cyclodextrin solubilization of water-insoluble drugs: calcipotriol and EB-1089. Pharmazie 52(10), 783–785 (1997)

    CAS  Google Scholar 

  16. Demirel, M., Yurtdaş, G., Genç, L.: Inclusion complexes of ketoconazole with beta-cyclodextrin: physicochemical characterization and in vitro dissolution behaviour of its vaginal suppositories. J. Incl. Phenom. Macrocycl. Chem. 70, 437–445 (2011)

    Article  CAS  Google Scholar 

  17. Bandarkar, F.S., Vavia, P.R.: An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β-cyclodextrin. Drug Dev. Ind. Pharm. 37(11), 1318–1328 (2011)

    Article  CAS  Google Scholar 

  18. Kakran, M., Sahoo, N.G., Li, L., Judeh, Z.: Dissolution enhancement of artemisinin with β-cyclodextrin. Chem. Pharm. Bull. 59(5), 646–652 (2011)

    Article  CAS  Google Scholar 

  19. Yan, Z., Xu, W., Sun, J., Liu, X., Zhao, Y., Sun, Y., Zhang, T., He, Z.: Characterization and in vivo evaluation of an inclusion complex of oridonin and 2-hydroxypropyl-β-cyclodextrin. Drug Dev. Ind. Pharm. 34, 632–641 (2008)

    Article  CAS  Google Scholar 

  20. Wang, L., Zeng, F., Zong, L.: Development of orally disintegrating tablets of perphenazine/hydroxypropyl-β-cyclodextrin inclusion complex. Pharm. Dev. Technol. (2012). doi:10.3109/10837450.2012.700932

  21. Dandawate, P.R., Vyas, A., Ahmad, A., Banerjee, S., Deshpande, J., Swamy, K.V., Jamadar, A., Dumhe-Klaire, A.C., Padhye, S., Sarkar, F.H.: Inclusion complex of novel curcumin analogue CDF and β-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Pharm. Res. 29, 1775–1786 (2012)

    Article  CAS  Google Scholar 

  22. Kutner, A., Chodynski, M., Leszczynska, K., Szelejewski, W., Fıtak, H.: Process for the preparation of calcipotriol. Patent number: US 20100222614 (2010)

Download references

Acknowledgments

This study was supported by Management of Scientific Research Projects of Ankara University (Project Number: 07B3336002). The authors would like to thank Embil Drug Company (Turkey) for their support in supplying calcipotriol.

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara University, 06100, Tandoğan, Ankara, Turkey

    Ulya Badilli, Gülin Amasya, Tangül Şen & Nilüfer Tarimci

Authors
  1. Ulya Badilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gülin Amasya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tangül Şen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nilüfer Tarimci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nilüfer Tarimci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Badilli, U., Amasya, G., Şen, T. et al. Topical emulgel formulation containing inclusion complex of calcipotriol with cyclodextrin. J Incl Phenom Macrocycl Chem 78, 249–255 (2014). https://doi.org/10.1007/s10847-013-0293-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10847-013-0293-2

Keywords

Search

Navigation